Aggregated China Business Blogs



China Biotech Week in Review: Benda Pharma Qualifies for Nasdaq Listing

Aggregated Source: Seeking Alpha China stocks
September 24, 2007|

Benda Pharmaceutical (BPMA.OB) announced the appointment of a third independent board member. With three outside board members, Benda’s board is now “independent” under Nasdaq rules and qualifies Benda to apply for listing on the Nasdaq exchange. Benda, through its China subsidiary, SiBiono, offers the gene therapy for cancer, Gendicine.

Original URL: Click here to visit original article
Copyright Seeking Alpha China stocks

Print This Post Print This Post | Email This Page Email This Page
No Ratings Yet
Loading ... Loading ...

Related Info:
  • Benda Makes Moves Toward American Exchange Listing
  • Biotech Week in Review: East-West Pharma Interaction
  • China Biotech Week in Review: East-West Pharma Interaction
  • Biotech Week in Review: Cross Border China Pharma Activity
  • Earnings and More in China Biotech Weekly Review

    • No Comments Yet »

    Your comment

    The following HTML tags are permitted:
    <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

    RSS RSS Feed for Comments on this Post |